A Review on Nanocarrier for Combination Delivery for Skin Cancer

One of the main causes of death globally, cancer continues to be a serious health issue. In 2018, an estimated 9.6 million people died from cancer, while 18 million new cases were diagnosed Aim to lower death rates and stop the spread of cancer As skin cancer spreads worldwide, more and more individuals are becoming victims of its frequently lethal effects. Globally, the number of skin cancer cases has surged, with the United States leading the way. Skin tumors are characterized according to their source cell and clinical aspects Squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and cutaneous malignant melanoma, often known as melanoma are the two primary forms of non-melanoma skin cancer (NMSC). Through the introduction of novel techniques for both diagnosis and therapy, nanotechnology has recently transformed the field of cancer research. Developments in nanomaterials, including quantum dots and gold nanoparticles, have greatly improved molecular diagnostics. These nanotechnology-based instruments aid in the creation of biomarkers, which facilitate quicker and more accurate cancer diagnosis and bolster early detection initiatives. Moreover, researchers have shown strong interest in applying nanosystems for drug delivery. Nanosystems that can precisely deliver chemotherapeutic drugs into the tumor microenvironment and transcend biological barriers have been made possible by advancements in this field

Nanocarriers In Drug Delivery for Skin Cancer

Numerous research have looked at using nanoparticles to co-deliver medicinal drugs for the treatment of skin cancer11.The aggregation of nanocarriers in malignant growing tissue with a defective vascular enhances their maintenance impact and porosity. Patients could receive chemotherapy with this. Liposomes, polymeric nanoparticles, dendrimers, gold nanoparticles, magnetic nanoparticles, and quantum dots are only a few of the nanocarriers that can be used to treat skin malignant tumors Because of their distinct physical and chemical characteristics, nanocarrier-based delivery systems can act as artificial platforms for diagnostic agents, offering cancer patients greater hope by aiding in the detection and monitoring of tumors [15]. Nanotechnology also makes it possible to deliver proteins, DNA, and medications precisely to tumors, reducing the possibility that these materials would inadvertently build up in nearby tissues.  By facilitating the targeted transport of medications to malignant tissues, the increased permeability and retention (EPR) effect of nanomedicine offers enormous potential for more precise tumor targeting. Certain medications' ability to attach selectively to components of cancer cells or the tumor microenvironment enhances this targeted precision even further, safeguarding healthy tissues and enhancing treatment outcomes. By enhancing the solubility of weakly water-soluble medications, reducing immunological reactions, prolonging circulation time, changing pharmacokinetics, and boosting bioavailability, nanoparticles also improve medicinal efficacy. Additionally, they facilitate the co- administration of many medicines in combination therapy and permit regulated drug release

Nanoparticle-Based Systems for Drug Delivery Applications:

While there are several additional types of nanoparticles used in drug delivery, the most often used ones include liposomes, polymeric, gold, dendrimers, and quantum dots. The advantages and disadvantages of various nanoparticles are listed in Table 01.

The intracellular concentration of therapeutic medicines can be raised by using nanoparticles to deliver medications to target cells more precisely. Following chemotherapy, this accuracy is particularly crucial since cancer cells may become resistant to repeated medication treatments. This technique uses a variety of agents and stabilizers. Important roles are played by biomolecules found in plant extracts, including proteins, polyphenols, flavonoids, reducing sugars, polysaccharides, alkaloids, amino acids, vitamins, and ketones. A plant must possess at least one chemical that can reduce metal ions to their elemental form in order to be chosen for biosynthesis. After Au³⁺ ions are first reduced to Au⁰, the gold surface is coated to stabilize the nanoparticles and stop them from aggregating. Fungal autolysate, intracellular synthesis, or extracellular synthesis are the three methods by which fungi can produce gold nanoparticles. Both the specific fungal strain and the experimental setup affect the final nanoparticles' size and dispersion

2. Findings and Applications for the Future

The application of GNP conjugates for drug administration has seen some notable developments over the past ten to fifteen years, however there are still challenges. Because of their improved bioavailability, longer treatment duration and circulation, and less side effects from their specialized impact on cancer cells, medicines conjugated with GNPs, whether antibacterial or anticancer, often exhibit superior effectiveness than their free equivalents.

Dendrimers in Drug Delivery

The use of gnp conjugates for drug delivery has seen several important developments over the past ten to fifteen years although there are still challenges drugs conjugated with gnps whether antibacterial or anticancer often exhibit greater effectiveness than their free counterparts due to their improved bioavailability longer therapeutic duration and circulation and less side effects from their targeted action on cancer cells known as dendrimers these highly homogeneous extensively branching macromolecules consist of a central core many internal layers called generations and an exterior terminal functional group their exact control over size shape and surface properties is made possible by their well-defined structure which makes them ideal candidates for drug delivery systems they can bind to their surface or encase medications to release therapeutic molecules in a specific and regulated way figure 03 displays the dendrimer structure.

1. Mechanism of Drug Delivery

By using the enhanced penetration and retention epr effect in tumor tissues dendrimers make passive targeting possible by altering their surfaces with ligands like folic acid or antibodies dendrimers can actively target cancer cells controlled release surface groups and internal cavities can produce ph-sensitive or enzyme-responsive drug release to minimize harm to healthy tissues

Fig.01: D structure of dendrimers

2. Applications in Drug Delivery

Because of their special capacity to deliver medications precisely and precisely, dendrimers are becoming more potent instruments in nanomedicine. Enhancing anticancer medications' internal behavior is one of the main issues facing cancer treatment today. Attaching polymers to these medications has shown promise in making them more stable, soluble in water, and less likely to cause unintended immune reactions. In solid tumors, drug–dendrimer conjugates tend to accumulate at the target site, which not only improves solubility but also limits harmful side effects elsewhere in the body. Researchers have explored different ways to load therapeutic agents, genetic material, targeting ligands, and imaging dyes into dendrimers through encapsulation, complexation, or chemical bonding taking advantage of their highly organized structures. Because of these features, dendrimers are opening new possibilities in both cancer treatment and diagnostic imaging. Recent studies, for example, highlight how poly(amidoamine) (PAMAM) dendrimers can carry drugs like 5-fluorouracil and methotrexate directly into skin cancer cells, enhancing drug penetration and retention in tumors while reducing toxicity to the rest of the body

Advantages

when administered with controlled release devices targeted administration minimizes damage to healthy cells by concentrating medication treatments on diseased areas at lesser dosages drugs can have long- lasting therapeutic effects when drugs that arent very soluble in water become more soluble this is known as bioavailability these devices versatility allows for simultaneous imaging and therapy which makes it possible to employ cutting-edge techniques like theranostics.

3. Challenges and Future Perspective

concerns such potential cytotoxicity immunogenicity and manufacturing scalability persist despite promising results future research should focus on long-term safety studies regulatory approvals and the development of cost-effective production methods for the targeted administration of drugs in the treatment of skin cancer dendrimer nanoparticles provide a flexible and efficient platform because of their distinct structural characteristics drugs may be administered precisely which may enhance patient outcomes and lessen adverse effects more studies and clinical trials are required to fully comprehend their potential in cancer

Liposomes In Drug Delivery

Nanotechnology's particular benefits in drug transport, imaging, and diagnostics have led to a growing awareness of its potential in cancer treatment. Preclinical and clinical studies have examined a variety of nanocarriers; those that combine many advantageous characteristics have significant therapeutic potential. Some examples that have been employed to improve the administration of therapies including immunotherapy, radiation therapy, gene therapy, and chemotherapy are liposomes, polymeric micelles, inorganic nanoparticles, drug conjugates, and virus-like nanoparticles. The limitations of cancer vaccines, tyrosine kinase inhibitors, and therapeutic monoclonal antibodies have been steadily addressed by nanotechnology-based approaches, in addition to notable advancements in immunotherapy. Liposomes are a promising nanotechnology-based approach in cancer immunotherapy. These lipid-based nanoparticles have been applied in numerous clinical trials for purposes such as vaccination and targeted cancer treatments. One notable liposomal formulation, Doxil, has received approval for cancer therapy. Because liposomes can encapsulate or associate with a variety of therapeutic agents including peptides, proteins, antibodies, and small-molecule chemotherapeutics. They offer significant potential to enhance the effectiveness of cancer immunotherapies

1. Liposomes: Structure and Advantages Enclosing aqueous solutions, liposomes are spherical vesicles made of one or more biological bilayer membranes. Hydrophilic polar head groups, which can be negatively charged or zwitterionic, carrying both positive and negative charges [56-60], and hydrophobic hydrocarbon chains, which vary in length and degree of unsaturation, make up their basic structures60.One of the main benefits of liposomes is their great biocompatibility and biodegradability. They have the capacity to encapsulate a wide variety of medications and can better target sick tissues by taking advantage of the increased permeability and retention (EPR) effect. In order to facilitate active targeting, their surfaces can also be altered, for example, by ligand attachment or PEGylation. Additionally, liposomes facilitate prolonged and regulated medication release, which improves therapeutic effectiveness.
2. Delivery Mechanism for Skin Cancer Drug Liposomes can be injected intravenously to build up at tumor sites by taking advantage of the increased permeability and retention (EPR) effect, or they can be used topically to improve medication penetration through the stratum corneum in the treatment of skin cancer. Endocytosis is the process by which liposomes are swallowed by cancer cells after they reach their target area, enabling the intracellular release of their therapeutic payload. To improve treatment accuracy, liposomes can also be functionalized with targeting molecules, such peptides or antibodies, that bind to receptors like integrins and EGFR that are overexpressed on skin cancer cells. development and postponed disease progression in experimental models of 4T1 breast cancer and CT26 colorectal cancer.
3. Types of Liposomes Used in Skin Cancer Therapy

• Conventional Liposomes: Composed of simple lipid bilayers; circulation time is limited due to rapid clearance by the reticuloendothelial system (RES).
• Stealth Liposomes (PEGylated): Coated with polyethylene glycol (PEG) to avoid immune recognition and extend circulation time.
• Targeted Liposomes: These are peptides or antibodies that work to target certain receptors.
• Stimuli-Responsive Liposomes: Made to release medications in reaction to particular stimuli, including altered pH, temperature, or enzymes found in the tumor microenvironment

4. Applications in Skin Cancer

A variety of drugs have been incorporated into liposomes to improve the efficacy of skin cancer treatment for example encapsulating doxorubicin enhances tissue penetration while minimizing cardiotoxicity similarly liposomal delivery of 5- fluorouracil 5-fu increases retention in the skin and reduces the risk of local irritation natural compounds such as curcumin and resveratrol which possess anticancer properties also experience enhanced solubility and stability when administered via liposomal carriers Liposome-based therapies enable site-specific treatment of breast cancer, enhancing the therapeutic efficacy of the associated drug by improving its pharmacokinetics and pharmacodynamics and ensuring delivery to the targeted site. Despite being powerful anticancer medications, anthracyclines harm the body's rapidly dividing cells, such as the blood, hair follicles, and the gastrointestinal tract's mucosa. To assist prevent this off-target damage, these medications are encapsulated in liposomes. Because liposomal delivery concentrates the drug at the tumor site, it improves therapeutic efficacy and reduces negative side effects.

5. Advantages Over Conventional Therapy Liposome nanocarriers are superior to traditional cancer therapies in a number of ways. By enabling localized medication delivery, they safeguard healthy tissues and lessen systemic toxicity. The stability and bioavailability of the encapsulated medications are improved, and treatment accuracy is increased due to their capacity to accumulate at tumor locations. By reducing the possibility of adverse effects, these qualities frequently enable efficient therapy with lower dosages. Liposomes are also adaptable for combination treatments, including combining photodynamic therapy and chemotherapy, which offers a more thorough and efficient method of managing cancer.
6. Challenges and Future Directions

Liposome nanocarriers have a great deal of potential, but in order to increase their therapeutic value, a number of issues need to be resolved. Two significant challenges still remain: scaling up manufacturing and maintaining stability during production. Effective medication penetration for topical treatments is restricted by the skin barrier, and the sophisticated nature of these nanocarrier systems complicates regulatory clearance procedures. To assure long-term safety and efficacy, future research is thus concentrating on creating multifunctional liposomes that may integrate therapeutic administration with diagnostic imaging, investigating patient-specific customized nanomedicine techniques, and carrying out extensive clinical studies

Quantum Dots

There are several reasons why liposome nanocarriers are better than conventional cancer treatments. They reduce systemic toxicity and protect healthy tissues by facilitating localized drug delivery. Because the encapsulated drugs may concentrate at tumor sites, their stability and bioavailability are enhanced, and therapy accuracy is raised. These characteristics often allow effective treatment with lower doses by decreasing the likelihood of side effects. Additionally, liposomes may be modified for combination therapies, such as combining chemotherapy with photodynamic therapy, which provides a more comprehensive and effective way to treat cancer. Skin cancer is still one of the most prevalent malignancies in the world, including melanoma and non-melanoma types. Although traditional therapies like chemotherapy, radiation, and surgery are often used, they frequently have drawbacks such drug resistance, systemic side effects, and inaccurate targeting. To improve the accuracy and efficacy of drug administration in this environment, nanotechnology- specifically, quantum dots-offers a unique platform, especially when paired with imaging tools for more precise and customized skin cancer therapy

1. Structure and Properties of Quantum Dots To improve photostability and biocompatibility a semiconductor core such as cdse or cdte is often wrapped in a shell material such as zns in quantum dots their size-dependent fluorescence allows for precise visualization of cells and substances moreover biological substances that can be utilized to functionalize their surfaces include peptides antibodies and pharmaceutical drugs
2. Mechanism of Quantum Dot-Based Drug Delivery

Quantum dots combine real-time imaging and tailored medication delivery to create efficient theranostic agents. They can more precisely deliver drugs by preferentially binding to receptors that are overexpressed on cancer cells when coupled with certain ligands, such folic acid. Furthermore, it is possible to create quantum dots that will release therapeutic chemicals in response to enzyme activity, temperature changes, or pH variations, allowing for targeted and regulated therapy. Additionally, their inherent fluorescence makes it possible to track the location of tumors and the distribution of drugs in real time, which offers useful feedback throughout treatment

3. Applications in Skin Cancer

Diagnostic Imaging:

Because they make tumor-specific biomarkers more visible quantum dots qds are highly effective imaging techniques for the early diagnosis of melanoma64 the precision of tumor localization is enhanced by their strong and consistent fluorescence

Drug Delivery

Molanoma cells have been effectively treated with doxorubicin and other chemotherapeutic drugs using quantum dots (QDs). Research demonstrates enhanced cytotoxic effects on cancer cells while minimizing damage to nearby healthy tissues

Photodynamic and Photothermal Therapy

As energy donors in photodynamic treatment (PDT), quantum dots (QDs) trigger photosensitizers that produce reactive oxygen species, which destroy cancer cells. QDs use photothermal treatment to locally ablate tumor tissues by converting near-infrared light into heat

4. Benefits of Using Quantum Dots

Quantum dots provide several key advantages in biomedical applications, especially in cancer therapy. Their high specificity and selectivity enable precise targeting of diseased cells, greatly improving therapeutic accuracy. Owing to their multifunctional capabilities, they can simultaneously facilitate both imaging and drug delivery, making them well-suited for integrated diagnostic and therapeutic strategies. Efficient targeting also allows for lower drug doses, minimizing potential side effects. Additionally, the surface of quantum dots can be readily modified with various functional groups, offering flexibility for tailored applications.

5. Challenges and Limitations

There are some disadvantages to quantum dots despite their great potential. Since many quantum dots include potentially hazardous heavy metals like cadmium, toxicity is a major issue. Because of their inadequate body clearance and low biodegradability, they also raise long-term safety concerns. These concerns, in addition to regulatory barriers and a lack of comprehensive long-term safety data, have hindered the widespread adoption of quantum dot-based medications in clinical settings.

6. Future Directions

Current research is focusing on alternatives such as carbon- and silicon-based quantum dots, which are non-toxic and biodegradable. Additionally, developments in biosensors, microneedle patches, and combination therapies (for example, QDs paired with siRNA) are being explored to enable more personalized and effective treatments

Polymeric Nanoparticles:

For targeted drug delivery, polymeric nanoparticles (PNPs) have become a flexible and exciting platform in nanomedicine. Because of their adaptable size, safe degradability, biocompatibility, and capacity to transport a variety of therapeutic substances, they are ideal for the treatment of skin cancer. This study focuses on melanoma and discusses current developments in the design and production of polymeric nanoparticles, as well as their processes and uses in the treatment of skin cancer. It also discusses the difficulties facing this subject now and possible future paths. For targeted drug delivery in nanomedicine, polymeric nanoparticles (PNPs) have shown great promise and versatility. Skin cancer can be effectively treated with them because of their customizable size, biocompatibility, biodegradability, and capacity to carry a broad range of therapeutic chemicals. Recent developments in the synthesis and engineering of polymeric nanoparticles are reviewed in this article, along with an investigation into their modes of action and potential uses in the treatment of skin malignancies, especially melanoma. It also talks about the difficulties that exist now and outlines possible paths forward in this field

1. Overview of Polymeric Nanoparticles

Natural or manufactured polymers, including polylactic acid (PLA), chitosan, poly(lactic-co-glycolicacid) (PLGA), and polyethylene glycol (PEG), combine to form polymeric nanoparticles, which are colloidal systems. In general, they are between 10 and 1000 nmin size and may be designed to encapsulate both hydrophilic and hydrophobic medications

2. Types of Polymeric Nanoparticles

• Nanospheres: Matrix-type systems in which the drug is evenly distributed throughout.
• Nanocapsules: Core–shell structures consisting of a drug-filled core enclosed by a polymeric shell [69-71].

3. Common Polymers Used

PLGA: Biodegradable polymer approved by the FDA.

Chitosan: Exhibits mucoadhesive properties and improves skin permeability.

PEG: Extends circulation time and lowers immunogenicity.

4. Drug Delivery Mechanism

Because of their nanoscale size and surface characteristics, polymeric nanoparticles can pass through the stratum corneum and settle in the deeper layers of the skin. Multiple pathways can lead to the release of drugs from these nanoparticles: stimuli- responsive release, which is triggered by particular factors like pH shifts, temperature changes, or enzymatic activity at the tumor site; diffusion- controlled release, where the drug slowly moves through the polymer matrix; and erosion-controlled release, which involves the degradation of the polymer to free the drug

5. Applications in Skin Cancer Therapy Chemotherapy Delivery: Polymeric nanoparticles (PNPs) better encapsulate medications like doxorubicin or paclitaxel, increasing their solubility, bioavailability, and tumor cell-specific absorption. Studies have demonstrated that melanoma cells are more susceptible to cytotoxicity whereas healthy cells are less susceptible.

Topical Delivery: Polymeric nanoparticles applied topically enhance drug penetration and retention in the skin, making them well-suited for treating superficial skin cancers. Chitosan-based PNPs, in particular, have demonstrated effective delivery across the skin barrier. Gene Therapy and Immunotherapy: Polymeric nanoparticles can be utilized to carry siRNA/miRNA and immunomodulatory drugs to alter cancer cells or strengthen the immune system. For instance, PLGA nanoparticles containing anti-PD-1 antibodies have shown encouraging results in models of melanoma.

Photodynamic Therapy: Polymeric nanoparticles can encapsulate photosensitizing agents for localized, light- triggered cytotoxic effects. Controlled release upon irradiation helps minimize damage to surrounding healthy skin

6. Advantages of Polymeric Nanoparticles in Skin Cancer

The use of polymeric nanoparticles in skin cancer therapy offers several advantages, including the ability to deliver medications to tumor cells precisely, control and sustain drug release, improve drug stability and solubility, lower systemic toxicity, and integrate therapeutic agents with imaging molecules for multifunctional treatment strategies

7. Challenges and Limitations

Notwithstanding their potential, polymeric nanoparticles face a number of difficulties and restrictions. Their ability to penetrate the skin can be restricted by the stratum corneum's ability to function as a barrier. These nanoparticles' stability and integrity may also be impacted by environmental influences. Because of safety and long-term toxicity concerns, only a small number of formulations have advanced to clinical trials, making it difficult to scale up manufacturing while maintaining consistent quality and regulatory obstacles

FUTURE PERSPECTIVES

The development of intelligent, stimuli-responsive systems that react to certain triggers is the main goal of future polymeric nanoparticle research. The integration of these nanoparticles with microneedle patches to improve medication delivery and epidermal penetration is gaining traction. Additionally, biodegradable natural polymers like alginate and hyaluronic acid are being used more often. Furthermore, a promising avenue for more potent treatments for skin cancer is provided by individualized nanomedicine strategies catered to specific tumor indicators

CONCLUSION

For targeted treatment of skin malignancies such as melanoma, squamous cell carcinoma, and basal cell carcinoma, nanocarriers are a potential development. Liposomes, polymeric nanoparticles, dendrimers, gold nanoparticles, and quantum dots are examples of nanocarriers that carry medications straight to the tumor location, overcoming the drawbacks of traditional chemotherapy. Therapeutic efficacy is increased and systemic toxicity is decreased by this focused administration. There are unique benefits and drawbacks associated with each form of nanoparticle. Their shown promise in diagnosis and therapy need more study to assure their safety and enable practical usage.

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
2. Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. 2017; 6:44.
3. Bilal M, Iqbal HM. New insights on unique features and role of nanostructured materials in cosmetics. Cosmetics. 2020;7(2):22.
4. Urban K, Mehrmal S, Uppal P, Giesey RL, Delost GR. The global burden of skin cancer: A longitudinal analysis from the Global Burden of Disease Study, 1990–2017. JAAD Int. 2021; 2:98– 108. doi: 10.1016/j.jdin.2020.10.013
5. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069–80. doi:10.1111/j.1365- 2133.2012.10830.x
6. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542(7639):115–8. doi:10.1038/nature21056
7. Khan NH, Mir M, Qian L, et al. Skin cancer biology and barriers to treatment: Recent applications of polymeric micro/nanostructures. J Adv Res. 2022; 36:223–47.
8. Raza A, et al. Zein-based micro-and nano- constructs and biologically therapeutic cues with multi-functionalities for oral drug delivery systems. J Drug Deliv Sci Technol. 2020; 58:101818.
9. Din F, Aman W, Ullah I, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. 2017; 12:7291–309. doi:10.2147/IJN.S146315
10. Jin C, Wang K, Oppong-Gyebi A, Hu J. Application of nanotechnology in cancer diagnosis and therapy—a mini-review. Int J Med Sci. 2020;17(18):2964–73. doi:10.7150/ijms.49801
11. Afsharzadeh M, Hashemi M, Mokhtarzadeh A, Abnous K, Ramezani M. Recent advances in co- delivery systems based on polymeric nanoparticles for cancer treatment. Artif Cells Nanomed Biotechnol.       2018;46(6):1095–110. doi:10.1080/21691401.2017.1376675
12. Sun Y, Kang C, Zhang A, et al. Co-delivery of dual- drugs with nanoparticles to overcome multidrug resistance. Eur J Med Res. 2016;2(2):12–8.
13. Jain R, Sarode I, Singhvi G, Dubey SK. Nanocarrier based topical drug delivery—A promising strategy for treatment of skin cancer. Curr Pharm Des. 2020;26(36):4615–23. doi:10.2174/1381612826666200826140448
14. Akhter MH, Rizwanullah M, Ahmad J, Ahsan MJ, Mujtaba MA, Amin S. Nanocarriers in advanced drug targeting: setting novel paradigm in cancer therapeutics. Artif Cells Nanomed Biotechnol. 2018;46(5):873–84. doi:10.1080/21691401.2017.1366333
15. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007; 24:1–16.
16. Hare JI, et al. Challenges and strategies in anti- cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017; 108:25–38.
17. Li Z, et al. Influence of nanomedicine mechanical properties on tumor targeting delivery. Chem Soc Rev. 2020;49(8).
18. Emerich DF, Thanos CG. The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomol Eng. 2006;23(4).
19. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665).
20. Lu W, Huang Q, Ku G, et al. Photoacoustic imaging of living mouse brain vasculature using hollow gold nanospheres. Biomaterials. 2010;31(9):2617–26.
21. Albrecht R. Immunocytochemistry: A Practical Approach. 2nd ed. Oxford: Oxford University Press; 1993.
22. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces. 2008;66(2):274–80.
23. Nazir S, Hussain T, Ayub A, Rashid U, Macrobert AJ.  Nanomaterials in combating cancer: therapeutic           applications and         developments. Nanomedicine. 2013;10(1):19–34.
24. Dreaden EC, Austin LA, MacKey MA, El-Sayed MA. Size matters: gold nanoparticles in targeted cancer drug delivery. Therapeutic Delivery. 2012;3(4):457–78.
25. Qian X, Peng X, Ansari DO, et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol. 2008;26(1):83–90.
26. Jokerst JV, Gambhir SS. Molecular imaging with theranostic nanoparticles. Acc Chem Res. 2011;44(10):1050–60.
27. Kimling J, Maier M, Okenve B, et al. Turkevich method for gold nanoparticle synthesis revisited. J Phys Chem B. 2006;110(32):15700–7.
28. Hainfeld JF, Dilmanian FA, Slatkin DN, Smilowitz HM. Radiotherapy enhancement with gold nanoparticles. J Pharm Pharmacol. 2008;60(8):977– 85.
29. Pan Y, Neuss S, Leifert A, et al. Size-dependent cytotoxicity of gold nanoparticles. Small. 2007;3(11):1941–9.
30. Eyvazzadeh N, Shakeri-Zadeh A, Fekrazad R, et al. Gold-coated magnetic nanoparticles as nanotheranostic agents for MRI and photothermal therapy of cancer. Lasers Med Sci. 2017; 32:1469– 77.
31. Kennedy LC, Bickford LR, Lewinski NA, et al. A new era for cancer treatment: gold-nanoparticle- mediated thermal therapies. Small. 2011; 7:169–83.
32. Day ES, Zhang L, Thompson PA, et al. Vascular- targeted photothermal therapy of an orthotopic murine glioma model. Nanomedicine. 2012; 7:1133–48.
33. Biosciences IN. Pilot study of AuroLase therapy in refractory and/or recurrent tumors of the head and neck. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000.
34. Biosciences N. Inc. Efficacy study of AuroLase therapy in subjects with primary and/or metastatic lung tumors. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000.
35. Alkilany AM, Murphy CJ. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J Nanopart Res. 2010; 12:2313–33.
36. Monopoli MP, Åberg C, Salvati A, et al. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012; 7:779–86.
37. Dai Q, Walkey C, Chan WC. Polyethylene glycol backfilling mitigates the negative impact of the protein corona on nanoparticle cell targeting. Angew Chem Int Ed. 2014; 53:5093–6.
38. Walkey CD, Chan WC. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev. 2012; 41:2780–99.
39. Kekicheff P, Schneider GF, Decher G. Size- controlled polyelectrolyte complexes: direct measurement of forces involved in triggered collapse of layer-by-layer nanocapsules. Langmuir. 2013; 29:10713–26.
40. Oaew S, Charlermroj R, Pattarakankul T, et al. Gold nanoparticles/horseradish peroxidase encapsulated polyelectrolyte nanocapsule for signal amplification in Listeria monocytogenes detection. Biosens Bioelectron. 2012; 34:238–43.
41. Penders J, Stolzoff M, Hickey DJ, et al. Shape- dependent antibacterial effects of non-cytotoxic gold nanoparticles. Int J Nanomedicine. 2017; 12:2457.
42. Kim K, Oh KS, Park DY, et al. Doxorubicin/gold- loaded core/shell nanoparticles for combination therapy to treat cancer through enhanced tumor targeting. J Control Release. 2016; 228:141–9.
43. Kannan R, Zambre A, Chanda N, et al. Functionalized radioactive gold nanoparticles in tumor therapy. Wires Nanomed Nanobiotechnol. 2012; 4:42–51.
44. Gargioni E, Schulz F, Raabe A, et al. Targeted nanoparticles for tumor radiotherapy enhancement—the long dawn of a golden era? Ann Transl Med. 2016; 4:523.
45. Bagheri S, Yasemi M, Safaie-Qamsari E, et al. Using gold nanoparticles in diagnosis and treatment of melanoma cancer. Artif Cells Nanomed Biotechnol. 2018;46(sup1):462–71. doi:10.1080/21691401.2018.1430585
46. [Gold nanoparticles: Synthesis, properties, and applications]
47. [Drug delivery using gold nanoparticles]
48. Kesharwani P, et al. PAMAM dendrimer as a talented multifunctional biomimetic nanocarrier for cancer diagnosis and therapy. Colloids Surf B Biointerfaces. 2022; 204:111837.
49. Luong D, et al. PEGylated PAMAM dendrimers: enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery. Acta Biomater. 2016; 43:14–29.
50. Sun M, et al. Dendrimer-mediated drug delivery to the skin. Soft Matter. 2012;8(16):4301–5.
51. Mekuria SL, et al. Dendrimer-based nanogels for cancer nanomedicine applications. Bioconjug Chem. 2022;33(1):87–96.
52. [Nanocarriers in skin cancer treatment: Emerging drug delivery approaches and innovations. Nano TransMed. 2025; 4:100068]
53. Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010; 10:3223–30. doi:10.1021/nl102184c
54. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science.     2004; 305:200–5. doi:10.1126/science.1100369.